Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Genetron : 3Q21 Presentation

11/30/2021 | 05:41am EST

Genetron Holdings Limited

(Nasdaq: GTH)

3Q 2021 Financial Results

November 2021


The following presentation has been prepared by Genetron Holdings Limited ("Genetron Health" or the "Company") solely for informational purposes and should not be construed to be, directly or indirectly, in whole or in part, an offer to buy or sell and/or an invitation and/or a recommendation and/or a solicitation of an offer to buy or sell any security or instrument or to participate in any investment or trading strategy, nor shall any part of it form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities or otherwise. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this document shall be relied upon as a promise or representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance. You acknowledge that any assessment of the Company that may be made by you will be independent of this document and that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

This document contains certain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1953, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the Company's future financial or business performance, strategies or expectations. These statements typically contain words such as "believe," "may," "will," "could," "expects" and "anticipates" and words of similar import. Any statement in this document that is not a statement of historical fact is a forward-looking statement and involves known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by such forward-looking statements. There can be no assurance that the results and events contemplated by the forward looking statements contained herein will in fact occur. None of the future projections, expectations, estimates or

prospects in this document should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations,

estimates or prospects have been prepared are correct or exhaustive or, in the case of assumptions, fully stated in the document. The Company also cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time and which may be beyond the Company's control. The Company assumes no duty to and does not undertake to update any forward-looking statements to reflect actual results, changes in assumptions or changes in factors affecting these statements. Factors that may materially affect our results and those risks listed in filings with the Securities and Exchange Commission.

This document also contains non-IFRS financial measures, the presentation of which is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with International Financial Reporting Standards. In addition, the Company's calculation of these non-IFRS financial measures may be different from the calculation used by other companies, and therefore

comparability may be limited. The reconciliation of those measures to the most comparable IFRS measures is contained within this document or available at our website http://ir.genetronhealth.com.

This document speaks as of November 30, 2021. Neither the delivery of this document nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since that date.


Leading Precision Oncology Company in China

Diagnosis & Monitoring (TAM)

Early Screening (TAM)


Diagnosis: $6.7B1

MRD: $14B2

Biopharma Services Services

Biotech Industry: $0.5B1

Liver cancer: $7.2B1

CRC cancer: $23.0B1

Lung cancer: $5.8B1

LDT - Top player covering 500+ hospitals

IVD - 7 products approved; S5+Lung 8 NGS solution

MRD partnerships in blood and solid tumors

High growth Chinese biotech industry

#1 Ranking: 47 total biopharma partners

CDx demand is growing as NMPA increases focus on genomic testing for innovative drugs

HCCscreenTM -

  • FDA breakthrough device designation (NGS)
  • Leading prospective data
  • Commercialization roadmap

HCCscanTM -

  • PCR-basedassay expands market opportunity leveraging existing customer capabilities

Multi-cancer development with innovative technology in liquid biopsy

Three Proprietary Technology Platforms as foundation:

One-step Seq, Mutation Capsules, FusionScan

  1. Frost & Sullivan, Market potential in China as of 2023
  2. Euromonitor, Globalcan, Company internal estimates market potential


Table of Contents

  • Recent Events & Business Updates
  • 3Q2021 Financials
  • Milestones and Growth Strategy
  • Appendix


3Q 2021 & Recent Events Recap

Revenue growth with momentum across all major segments

  • Total revenue RMB 152.5 million for 3Q2021, 36.2% y/y revenue growth.
  • Gross margin improved to 69.0% vs 62.2% in 3Q2020
  • LDT revenue increased by 30.2% y/y to RMB 93.0 million
  • IVD revenue increased by 70.5% y/y to RMB 51.3 million

Early-screening business with first-mover advantage

  • Broadened HCC early screening strategy - GTH projects 2023 NMPA approvals for both assays
    • Initiated HCCscanTM trial (PCR assay) - targeting 9 clinical sites with 5,000 patients
    • HCCscreenTM trial (NGS assay) to begin enrollment in the next few months
  • Clinical results of early liver cancer screening product HCCscreenTM, were included in expert consensus and the October 2021 publication of Chinese Journal of Hepatology
  • CRC early screening (blood-based)preliminary case control data with >91% sensitivity and 95% specificity

MRD Partnership with leading biopharma companies

  • Formed a co-development agreement with AstraZeneca R&D China for personalized MRD tests for solid tumors
  • Solid tumor MRD data through publications by 1H22
  • Entered into an exclusive agreement with Fosun Pharma to commercialize Seq-MRD® for blood cancers in China

Diagnosis and biopharma segments progressed well

  • Obtained CE Mark for Onco PanScanTM, the Company's large panel product that covers over 800 genes
  • Established partnerships with NeoGenomics to drive global oncology drug R&D and development
  • Established partnerships with IMPACT Therapeutics to development of a synthetic lethal product pipeline


This is an excerpt of the original content. To continue reading it, access the original document here.


Genetron Holdings Ltd. published this content on 30 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 November 2021 10:40:07 UTC.

© Publicnow 2021
01/10GENETRON : Health Reiterates Full Year 2021 Revenue Guidance - Form 6-K
01/10Genetron Health Reiterates Full Year 2021 Revenue Guidance
01/10Genetron Holdings Limited Reiterates Full Year 2021 Revenue Guidance
2021Asian ADRs Decline in Wednesday Trading
2021BTIG Adjusts Genetron Holdings' Price Target to $17 From $21, Reiterates Buy Rating
2021Genetron Health's Social Contribution Campaign to Make Precision Medicine More Accessib..
2021Genetron Holdings Q3 Non-IFRS Loss Widens; Revenue Rises; Lowers 2021 Revenue Guidance
2021GENETRON : Health Announces Co-Development Agreement with AstraZeneca R&D China for Person..
2021Genetron Holdings Limited Reports Earnings Results for the Third Quarter and Nine Month..
2021GENETRON : 3Q21 Presentation
More news
Analyst Recommendations on GENETRON HOLDINGS LIMITED
More recommendations
Financials (USD)
Sales 2021 83,0 M - -
Net income 2021 -71,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -13,1x
Yield 2021 -
Capitalization 419 M 419 M -
Capi. / Sales 2021 5,04x
Capi. / Sales 2022 3,70x
Nbr of Employees 799
Free-Float -
Duration : Period :
Genetron Holdings Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENETRON HOLDINGS LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Last Close Price 4,71 $
Average target price 14,51 $
Spread / Average Target 208%
EPS Revisions
Managers and Directors
Si Zhen Wang Chief Executive Officer & Director
Ce Xu Chief Financial Officer
Wei-Wu He Chairman
Hai Yan Chief Scientific Officer & Director
Yu Chen Jiao Chief Technology Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-34.04%67 921
LONZA GROUP AG-13.71%53 315
IQVIA HOLDINGS INC.-13.38%46 690
SEAGEN INC.-13.93%24 331